PHARMACEUTICAL EXECUTIVE NEWSLETTER

In this ISSUE

The EFPIA Disclosure Experience: An Update

Understanding Competitive Intelligence

England Updates Innovation Scorecard

Top Story

Life Sciences’ Shifting Sands: Five Trends that Threaten the Status Quo

If pharma companies want to hold their own in the current climate, they must embrace rather than resist market change, writes Peter Muller
… /Read more/

2017 Real-World Evidence Benchmark Survey
Deloitte's 2017 Real-World Evidence Benchmark Survey shows that life sciences companies are making some progress in using RWE but still have opportunities to expand applications across the value chain, consider new channels to access RWD, and improve their overall capabilities.

Explore this research Today!

Strategy

Why Identity is Imperative for Pharma Companies

Pharma must develop digital identity strategies for creating seamless, safe and compliant customer journeys, writes Jamie Beckland
… /Read more/

Drug Safety

Bracing for Drug Tracing Mandate

The need to start now to meet compliance deadlines for the Drug Supply Chain Security Act is critical, writes Grey Bylo
… /Read more/

Drug Safety

The Lengthening Arm of Pharmacovigilance

Cheryl Key rounds up the expert debate on pharmacovigilance’s rise up the life sciences agenda
… /Read more/

Three Ways President’s Trump’s FDA Can Help to Cure Cancer

Curing cancer is not an impossibility anymore. Essential to any effort to achieve this will be the policies coming from President Trump's administration, writes James Nathanielsz
… /Read more/

Calendar

/ April 26–28: CBI’s 14th Annual Pharmaceutical Compliance Congress /

Washington, DC

/ June 6–7: Pharmaceutical Compliance Congress Canada /

Toronto, Canada

/ June 27–28: Publication and Clinical Trial Transparency /

Barcelona, Spain

/ September 14–15: Risk Based Global Monitoring 2017 /

Barcelona, Spain

/ October 24–25: 12^th Annual Value-Based Oncology Management /

Scottsdale, AZ

Winning the RAT race: A new Center of Excellence to drive development of regenerative medicines
Live Webinar: Tuesday, May 2 at 11:00am EDT

Industry update

//NightstaRx Ltd (Boston, MA) named Senthil Sundaram as Chief Financial Officer//RXi Pharmaceuticals (Marlborough, MA) announced that Gerrit Dispersyn, Dr. Med Sc. has been appointed Chief Development Officer, effective April 24, 2017.//Recursion Pharmaceuticals (Salt Lake City, UT) hired Dr. Yolanda Chong as Vice President of Biology. //Asana Medical (Miama Lakes, FL) appointed Brian W. Andersen as Chief Business Officer.//

Patient Centricity: Turning Rhetoric into Reality
On Demand

Learn more

advertise with us / print subscribe / digital subscribe / visit pharmexec.com